Galderma, an independent dermatology company, announces thatย it has received antitrust clearance fromย the USย authoritiesย andย has completed the acquisitionย ofย ALASTIN Skincare Inc, a specialty aesthetics company that develops physician-dispensed skincare products.ย Theย transaction was previously announced onย November 29, 2021.ย 

โ€œI am so happy to officially welcome the ALASTIN team to Galderma. As a part of our integrated dermatology approach, we are continuously seeking to add products that synergize with our premium portfolio – and ALASTIN is the perfect fit. 

The ALASTIN brandโ€™s proprietary and award-winning skincare technology, combined with Galdermaโ€™s world-class pipeline and innovation track record, represents an unparalleled opportunity for Galderma to better meet the needs of aesthetic professionals and patients, now and well into the future.โ€   

— Flemming ร˜rnskov, MD, MPH, Chief Executive Officer, Galderma

ALASTIN’s product offerings are backed by the patented TriHex Technology, a proprietary blend of peptides and active botanicals to support the appearance of rejuvenated skin. Thisย acquisition will enhance Galdermaโ€™s integrated dermatology platform with a comprehensive collectionย of scientifically proven products for daily skincare regimens and peri-procedural use, and underscoresย the companyโ€™sย commitment to be the partner of choice for aestheticย professionals.ย 

โ€œOur team is extremely excited to be joining the Galderma family, and our shared focus on customers and commitment to driving innovation means weโ€™re a winning combination. Galdermaโ€™s global reach and cutting-edge research and development platform will help deliver ALASTINโ€™s next growth phase and support further innovation of ALASTINโ€™s products.โ€  

— Diane S Goostree, President and CEO, ALASTIN Skincare

[Source: Galderma]